Matthew Taylor of UBS, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Increased Target from $138 to $142 on, Jan 27th, 2022.
Matthew has made no other calls on ABT in the last 4 months.
There are 10 other peers that have a rating on ABT. Out of the 10 peers that are also analyzing ABT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Danielle Antalffy of "SVB Leerink" Maintained at Hold with Increased Target to $140 on, Thursday, October 21st, 2021
- Simon Baker of "Redburn Partners" Initiated at Hold on, Thursday, October 14th, 2021
These are the ratings of the 8 analyists that currently disagree with Matthew
- Robbie Marcus of "JP Morgan" Maintained at Buy and Held Target at $125 on, Saturday, January 22nd, 2022
- Joanna Wiensch of "Citigroup" Maintained at Strong Buy with Increased Target to $154 on, Wednesday, December 15th, 2021
- Shagun Singh of "RBC Capital" Initiated at Buy and Held Target at $146 on, Friday, December 10th, 2021
- James Mainwaring of "Atlantic Equities" Upgraded from Hold to Buy and Held Target at $144 on, Wednesday, October 27th, 2021
- Raj Denhoy of "Jefferies" Maintained at Strong Buy with Increased Target to $145 on, Thursday, October 21st, 2021
- Marie Thibault of "BTIG" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, October 20th, 2021
- Larry Biegelsen of "Wells Fargo" Maintained at Buy and Held Target at $135 on, Sunday, October 10th, 2021
- Joshua Jennings of "TD Cowen" Maintained at Buy and Held Target at $140 on, Friday, October 8th, 2021
